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Because frequency, immunohistochemical, and clinical features of lung spindle cell carcinoma (SpCC) are
unknown, the author retrospectively surveyed and re-examined the 718 lung malignancy samples in our
hospital. As the results, three cases of SpCC were found; thus the incidence of SpCC was 0.4% of all lung
malignancies. Clinically, the age of the patients was 53, 70 and 75 years. Two patients were smokers and
another ex-smoker. The SpCC was initially detected by routine chest X-ray examination in all cases. All
cases were peripheral tumors, and the size was 4 cm, 5 cm, and 5 cm in diameter. All cases were treated
by chemotherapy, and operations were not performed for various reasons. The survival period was 8, 16
and 25 months. Histologically, all the three SpCC consisted of only malignant spindle cells with hyper-
chromatic nuclei and mitotic ﬁgures. Immunohistochemical results were as follows: pancytokeratin (3/
3), high molecular weight cytokeratin (0/3), CK5/6 (0/3), CK7 (2/3), CK14 (1/3), CK18 (3/3), CK19 (1/3),
CK20 (0/3), epithelial membrane antigen (0/3), vimentin (3/3), thyroid transcriptional factor-1 (0/3), p63
(1/3), CEA (0/3), surfactant apoprotein A (0/3), desmin (0/3), S100 protein (0/3), a-smooth muscle actin
(0/3), CD34 (0/3), p53 protein (3/3), chromogranin (0/3), synaptophysin (0/3), neuron-speciﬁc enolase (0/
3), CD56 (0/3), CD56 (0/3), KIT (0/3) and platelet-derived growth factor-a (0/3). These results suggest that
SpCC of the lung shows no differentiation. One case of the three SpCC was positive for p63, suggesting
that it may be derived from spindle cell differentiation of poorly differentiated squamous cell carcinoma.
In summary, the present study showed the frequency (0.4%) of SpCC of the lung of all lung malignancies.
Clinical features of the three SpCC were described. Further, the three cases of SpCC were immunohis-
tochemically investigated.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Sarcomatoid carcinoma of the lung is rare, and its incidence is
estimated in0.3–1.3%ofall lungmalignancies.1–5AccordingtotheWHO
classiﬁcation,5 sarcomatoid carcinoma of the lung is deﬁned as a group
of poorly differentiated non-small cell lung carcinoma that shows
sarcoma or sarcoma-like (spindle and/or giant cell) differentiation.
Sarcomatoid carcinoma is classiﬁed into the following ﬁve histological
variants: pleomorphic carcinoma, spindle cell carcinoma (SpCC), giant
cell carcinoma, carcinosarcoma, and pulmonary blastoma.5 SpCC is
deﬁnedasanon-small cell carcinomaconsistingofonlyspindle-shaped
tumor cells.5 Although other four variants of sarcomatoid carcinoma
have been investigated in several reports,1–8 there are no comprehen-
sive reports on SpCC of the lung, to the best of the author’s knowledge.
In addition, the incidence, clinical features, and immunohistochemicalrved.features of SpCC are unknown. Therefore, the author investigated SpCC
of the lung in the archival ﬁle of our laboratory.
2. Materials and methods
The author retrospectively surveyed and re-examined 718 cases
of lung cancer (biopsy, 586 cases; surgical, 132 cases) in recent 10
years in our hospital, and selected SpCC. The clinical records of the
selected SpCC of the lung were reviewed. An immunohistochemical
study was performed by Dako envision method (Dako Corp.,
Glostrup, Denmark) as previously described.9,10 The antigens
examined are shown in Table 1.
3. Results
3.1. Frequency
Three cases of SpCC out of the 718 cases were recognized.
Therefore, the frequency of SpCC of the lung was 0.4% of all lung
malignancies.
Table 1
Immunohistochemical reagents and results.
Antigens Antibodies (clone) Sources Case 1 Case 2 Case 3
Pancytokeratin AE1/3 Dako Corp. Glostrup, Denmark þþþ þþ þ
Pancytokeratin Polyclonal wide Dako þþ þþ þ
Pancytokeratin KL-1 Immunotech, Marseille, France þþþ þþ 
HMWCK 34bE12 Dako   
CK5/6 D5/16 Dako   
CK7 N1626 Dako þþþ  þþþ
CK14 LL002 Novocastra, Newcastle upon type, UK  þ 
CK18 DC10 Dako þþþ þ þ
CK19 RCK 108 Progen, Heidelberg, Germany þ  
CK20 K20.8 Dako   
EMA E29 Dako   
Vimentin Vim 3B4 Dako þþþ þþþ þ
TTF-1 8G7G3/1 Dako   
CEA Polyclonal Dako   
Desmin D33 Dako   
S100 protein Polyclonal Dako   
ASMA 1A4 Dako   
CD34 NU-4A1 Nichirei, Tokyo, Japan   
p53 protein DO-7 Dako þ þ þ
p63 4A4 Dako   þ
SAPA PE-10 Dako   
Ki-67 MIB-I Dako 85% 90% 20%
Chromogranin DAK-A3 Dako   
Synaptophysin Polyconal Dako   
NSE BBS/NC/VI-H14 Dako   
CD56 UJ13A Dako   
CD68 KP-1 Dako   
KIT Polyclonal Dako   
PDGFRA Polyclonal Santa Cruz, CA, USA   
þþþ, Strongly positive; þþ, moderately positive; þ, mildly positive; , negative.
EMA, epithelial membrane antigen; CEA, carcinoembryonic antigen; ASMA, a-smooth muscle antigen; SAPA, surfactant apoprotein A; NSE, neuron-speciﬁc enolase; PDGFRA,
platelet-derived growth factor receptor-a.
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Case 1: A 53-year-old man, a drug abuser, was pointed out to
have two tumors in the right lung at routine chest X-ray exami-
nation, and referred to our hospital. He was a smoker. Imaging
modalities showed peripheral two tumors (5 cm in diameter and
3 cm in diameter) in the right upper lobe and lymph node metas-
tases in the hilar and peribronchial lymph nodes. Clinical cytology
showed malignant cells, and a transbronchial lung biopsy revealed
an SpCC. Because he rejected operation, he was treated by
chemotherapy, and the tumor was reduced in size. The patient is
now alive 8 months after the diagnosis without remote metastases.Fig. 1. Histology of spindle cell carcinoma of lung. It is composed of malignant spindle
cells. HE, 200.Case 2: A 75-year-old man with severe dementia and schizo-
phreniawas referred to our hospital because of fever and aspiration
pneumonia. The patient was an ex-smoker. Imaging modalities
revealed a tumor measuring 5 cm in diameter in the peripheral left
lower lobe. A transbronchial lung biopsy revealed an SpCC. No
metastases were detected. Operationwas not performed because of
his mental status and age. Chemotherapy was performed, and the
tumor was reduced. The patient is now alive 25 months after the
ﬁrst manifestation.
Case 3: A 70-year-old man with diabetes mellitus, angina pec-
toris, and brain infarction was followed up in our hospital. He wasFig. 2. The carcinoma cells are strongly positive for pancytokeratin AE1/3. Immunos-
taining, 200.
Fig. 3. The carcinoma cells are strongly positive for cytokeratin 7. Immunostaining,
200.
Fig. 5. The carcinoma cells are strongly positive for cytokeratin 18. Immunostaining,
200.
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right upper lobe. Imaging modalities also revealed a tumor
measuring 4 cm in diameter in the right upper lobe. The tumor was
found to invade the pleura. A video-assisted thracoscopic biopsy
revealed an SpCC. Because his condition was poor, operation was
not performed. The patient was treated by chemotherapy, but he
died of respiratory failure 16 months after the ﬁrst presentation.
3.3. Morphologies
All the three SpCC cases were composed of only malignant
spindle cells (Fig. 1). There were nuclear hyperchromasia and many
mitotic ﬁgures. The immunohistochemical results are shown in
Table 1. Of pancytokeratins, AE1/3 and polyclonal wide spectrum
showed strong expression in all the three cases (Fig. 2). KL-1
showed moderate immunoexpression in 2/3 cases. Tumor cells
were negative for high molecular weight cytokeratin (34bE12),
cytokeratin (CK) 5/6, and CK20 in all the three cases. CK7 was
recognized in 2/3 cases (Fig. 3), CK14 in 1/3 case (Fig. 4), CK18 in 3/3
cases (Fig. 5), CK19 in 1/3 case (Fig. 6). Epithelial membrane antigen
was negative in all cases. Vimentin was strongly expressed in 3/3
cases (Fig. 7). Thyroid transcriptional factor-1 (TTF-1), CEA, desmin,
S100 protein, a-smoothmuscle actin, and CD34were negative in allFig. 4. The carcinoma cells are positive for cytokeratin 14. Immunostaining, 200.cases. P53 protein was positive in 3/3 cases (Fig. 8), and p63 was
positive in 1/3 case (Fig. 9). Surfactant apoprotein Awas negative in
all cases. Ki-67 labeling was high or very high (Fig. 10). No neuro-
endocrine markers (chromogranin, synaptophysin, neuron-speciﬁc
enolase, and CD56) were negative in all cases. CD68, KIT and
platelet-derived growth factor-a were negative in all cases.4. Discussion
All the present cases were composed of only malignant spindle
cells. No other histological elements were recognized, and giant
cells or pleomorphic cells were absent. The immunohistochemical
analysis showed positive reactions for CKs and vimentin and
negative reactions for desmin, S100 protein, a-smooth muscle
actin, and CD34. Ki-67 labeling is high and p53 proteinwas positive.
Therefore, the present three cases are not sarcomas but carcinomas.
The three cases, thus, fulﬁll the criteria of SpCC of the lung.
There have been no comprehensive reports of SpCC of the lung,
to the best of author’s knowledge. However, several SpCCs of the
lung were reported together with sarcomatoid carcinoma.1–3,6
The incidence of SpCC was unknown. In the present study, the
frequency of SpCC of the lung was 0.4% of all lung malignancies.Fig. 6. The carcinoma cells are positive for cytokeratin 19. Immunostaining, 200.
Fig. 7. The carcinoma cells are strongly positive for vimentin. Immunostaining, 200. Fig. 9. The carcinoma cells are positive for p63. Immunostaining, 200.
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Addis and Corrin6 reported that pancytokeratin (CAM 5.2 and LP
34) was present in SpCC of the lung. The present study investigated
three pancytokeratins, 34bE12, CK5/6, CK7, CK14, CK18, CK19, and
CK20. Of these, 4bE12, CK5/6, and CK20 were always negative,
while pancytokeratins and CK18 were always positive. Other CKs
examined showed variable results.
TTF-1, p63 and surfactant apoprotein A are expressed in bron-
chial epithelium, reserve cells and squamous epithelium, and type
II pneumocytes, respectively. In general, it has been accepted that
TTF-1 is a marker of adenocarcinoma and small cell carcinoma, p63
and CD5/6 of squamous cell carcinoma, and surfactant apoprotein A
of adenocarcinoma and alveolar carcinoma.11–19 In the present
study, TTF-1, CK5/6, and surfactant apoprotein A were negative in
all cases, and p63 was negative except for one case (case 3). CEA is
negative for all cases. These results suggest that the SpCC of lung is
undifferentiated carcinoma without differentiation. The present
case 3, which was positive for p63, may be derived from spindle cell
transformation of poorly differentiated squamous cell carcinoma.20
P53 protein was expressed in all the three cases in the present
study. P53 expression in SpCC of the lung has been reported only
once by Holst et al.21 They found p53 expression in 4/9 cases of
SpCC of the lung. The present study shows p53 protein in all theFig. 8. The carcinoma cells are positive for p53 protein. Immunostaining, 200.three cases of SpCC of the lung. Further, this observation supports
the malignant nature of the present tumors.
Ki-67 has not been reported in SpCC. The present cases showed
95%, 90% and 20% labeling indexes, indicating high proliferative
fraction in SpCC of the lung. This also supports the malignant
characters of the present tumors.
Neuroendocrine carcinoma frequently occurs in the lung, such
as small cell lung carcinoma and large cell neuroendocrine carci-
noma. In the present study, neuroendocrine markers (chromogra-
nin, synaptophysin, CD56, and neuron-speciﬁc enolase) were
negative, suggesting that the present tumors are not associated
with neuroendocrine differentiation.
There have been no reports of CD56, KIT and platelet-derived
growth factor-a in SpCC. The present cases were negative for CD56,
KIT, and platelet-derived growth factor-a, suggesting the present
tumors were not associated with histiocytic tumors and KIT-posi-
tive tumors such as neuroendocrine carcinomas and extra-
gastrointestinal stromal tumors.
In summary, the present study showed the incidence (0.4%) of
SpCC of the lung of all lung malignancies in our hospital. Clinical
features of the three SpCC were described. Further, the three cases
of SpCC were immunohistochemically investigated.Fig. 10. The Ki-67 labeling of tumor cells is very high (90%). Immunostaining, 200.
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